Your Options Request a formulary exception your doctor can argue medical necessity What to do if Wegovy is not covered Cardiovascular risk reduction if you have heart disease risk factors, Wegovy's FDA-approved indication (March 2024) strengthens your case Consider Zepbound as of October 1, 2026 it returns as an "additional preferred option" alongside Wegovy on most Aetna/CVS Caremark plans [10] Zepbound coverage on Aetna Switch plans during open enrollment if your employer offers multiple options, check for GLP-1 coverage Explore self-pay options NovoCare ($349/mo) and patient assistance may help Wegovy Cost Guide About Wegovy's FDA Approvals Important: Sleep Apnea Coverage Goes to Zepbound, Not Wegovy Note: Zepbound (tirzepatide), not Wegovy, was FDA-approved to treat obstructive sleep apnea (OSA) in adults with obesity on December 20, 2024
Sources NEJM (2025): Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Complementing mechanical therapy, probiotic interventions offer a promising microbial-centric approach
Increased Energy By improving metabolic efficiency and hormone balance, peptide therapy may help increase energy levels
The copper-peptide complex stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, activates antioxidant enzymes including superoxide dismutase, modulates inflammatory responses, and stimulates hair growth through follicle activation
Share your medication list and supplements